Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
AXON ENTERPRISE, INC. chief revenue officer Cameron Brooks reported a routine share disposition tied to taxes rather than a market trade. On June 1, 2026, 743.757 shares of common stock were withheld at $448.72 per share to cover tax liability from vesting restricted stock units. Following this tax-withholding event, Brooks directly holds 50,951.933 shares of Axon common stock.
Axon Enterprise Chief Legal Officer Isaiah Fields reported routine share dispositions related to tax withholding. On June 1, 2026, a total of 5,257.268 shares of common stock were disposed of at prices of $476.88 and $448.72 per share to settle tax liabilities from the vesting of restricted stock units, including awards under the Axon Enterprise, Inc. 2024 eXponential Stock Plan.
AXON ENTERPRISE, INC. director Jeri Williams reported a mix of stock award and sales. On May 29, 2026, she received 611 time-vested restricted stock units under Axon’s Amended and Restated 2022 Stock Incentive Plan, scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the company’s 2027 Annual Meeting of Shareholders.
On June 1, 2026, she completed two open-market sales totaling 629 shares of common stock: 223 shares at $455.45 per share and 406 shares at a weighted average price of $477.4333 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, she directly holds 1,141 shares of Axon common stock.
AXON ENTERPRISE, INC. director Caitlin Elizabeth Kalinowski reported mixed equity activity. On June 1, 2026, she completed a series of open-market sales totaling 564 shares of Axon common stock at prices including $484.11 and $473.32 per share, leaving her with 3,632 shares held directly. Earlier, on May 29, 2026, she received a grant of 611 time-vested restricted stock units under Axon’s Amended and Restated 2022 Stock Incentive Plan, scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the company’s 2027 annual meeting of shareholders.
AXON filing: a Form 144 notice reports a proposed sale of 5,969 shares of Common Stock tied to restricted stock vesting under a registered plan. The filing names Brittany Bagley as a holder and shows prior sales of 4,266 shares on 03/02/2026 with a reported value of $2,358,679.51.
SMITH GRAHAM reported acquisition or exercise transactions in this Form 4 filing.
AXON ENTERPRISE, INC. director Graham Smith received an equity award of 611 shares of Common Stock as a grant under the company’s stock incentive plan. This award is in the form of time-vested restricted stock units that vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Shareholders. Following this grant, Smith directly holds 3,629 shares of Axon common stock. The transaction reflects routine equity compensation rather than an open-market purchase or sale.
Partovi Hadi reported acquisition or exercise transactions in this Form 4 filing.
AXON ENTERPRISE, INC. director Hadi Partovi reported receiving a grant of 611 shares of common stock in the form of time-vested restricted stock units at a price of $0.00 per share. These units were granted under Axon’s Amended and Restated 2022 Stock Incentive Plan and are scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the date of Axon’s 2027 Annual Meeting of Shareholders. Following this award, Partovi directly holds 238,649 shares of Axon common stock.
Morgenfeld Todd R reported acquisition or exercise transactions in this Form 4 filing.
Axon Enterprise director Todd R. Morgenfeld received an equity grant of 611 shares of Common Stock in the form of time-vested restricted stock units. The units were granted at no cash cost and increase his direct holdings to 947 shares. The award is scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the date of Axon Enterprise, Inc.'s 2027 Annual Meeting of Shareholders.
GARNREITER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
AXON ENTERPRISE, INC. director Michael Garnreiter reported equity compensation awards rather than open-market trades. On May 29, 2026, he received two grants of common stock totaling several hundred shares at $0.00 per share as part of his director compensation. A footnote explains these are time-vested restricted stock units granted under Axon’s Amended and Restated 2022 Stock Incentive Plan, scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the company’s 2027 Annual Meeting of Shareholders. These transactions reflect routine, plan-based stock awards instead of discretionary buying or selling of Axon shares.
Brown Adriane M reported acquisition or exercise transactions in this Form 4 filing.
AXON ENTERPRISE, INC. director Adriane M. Brown received an equity grant of 611 shares of Common Stock on May 29, 2026 as a compensation award. The shares are in the form of time-vested restricted stock units granted under the company’s Amended and Restated 2022 Stock Incentive Plan.
The award is scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the date of Axon Enterprise, Inc.'s 2027 Annual Meeting of Shareholders. Following this grant, Brown directly holds 8,437 shares of Axon common stock, indicating a relatively small, routine director equity award rather than an open-market transaction.